.png){kind=logo}
US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.
Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.
HOW WE USE YOUR INFORMATION
-
to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
-
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
-
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;
-
to send marketing communications to you, if applicable and
-
to comply with our legal and regulatory obligations and bring and defend legal claims.
We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein).
We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.
If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
_edited.jpg)
Stefan Scherer, MD, PhD
Executive in Residence
Stefan joined GSK as Global Head Experimental Medicine overseeing translational medicine, biomarkers, companion diagnostics, and clinical/translational alliances. He is responsible for strategic and operational aspects of personalized healthcare across Phase 1 to Phase 4. Prior, he held the position of SVP Clinical Development and CMO in Cellectis, clinical-stage biotech specializing in allogeneic CAR-Ts. In this role, he was responsible for setting the medical and clinical development strategy of multiple assets, in addition to building a clinical team. During his tenure, he brought programs in AML and ALL to the clinic and an IND approval for a target in MM. Previously, Stefan served as Vice President and Head of EDS&I (Early Development, Strategy, and Innovation) in Novartis. In this role, Stefan led broad teams, both in the medical and commercial functions, that planned and executed oncology studies for early-stage compounds, identify and implementing innovative signal seeking investigator-sponsored trials. Prior to this, Stefan served as Vice President, Global Head Correlative Sciences, Translational Precision Oncology where he was responsible for translational activities, biomarker and diagnostics assay development of targeted therapies, immunotherapies, and cell-based therapies in both solid tumors and hematology. Before joining Novartis, Stefan worked at Biocartis as the CMO responsible for the assay development and diagnostic strategy of the company. For over six years, Stefan held positions of increasing responsibility at F. Hoffmann-La Roche/ Genentech, starting as the biomarker program leader for Avastin and soon after overseeing the biomarker work for the entire angiogenesis franchise. Stefan later served as Head Biomarkers and Translational Medicine in Pharma Development overseeing the biomarker, diagnostic, translational medicine in late-stage Oncology. During his tenure, he worked closely with external partners in academia and commercial entities to established multiple translational hubs to further accelerate scientific discoveries. Stefan received his M.D. from the University of Freiburg and University of Saarbruecken/ Homburg Medical School, Germany, and his Ph.D. in Biomedical Sciences from the University of Wuerzburg - Biocenter, Wuerzburg, Germany. Stefan earned a post-graduate degree in Bioinformatics from the Academy for postgraduate education with the Universities of Heidelberg and Mannheim, Germany.